On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.In August, the FDA approved ARS Pharmaceuticals’ Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients.Neffy is a ...

Shares of ARS Pharmaceuticals, Inc. (SPRY) have gained 10.4% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.67 indicates a potential upside of 67.6%.The mean estimate comprises three short-term price targets with a standard deviation of $4.04. While the lowest estimate of $22 indicates a 43.6% increase fr ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that seven abstracts will be featured tomorrow, Friday, October 25 at the 2024 ACAAI Annual Scientific Meeting taking place in Boston, Massachusetts. The posters highlight a wide range of studies focused on intranasal epinephrine ...

ARS Pharmaceuticals, Inc. (SPRY) closed the last trading session at $14.52, gaining 9.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.67 indicates a 76.8% upside potential. The average comprises three short-term price targets ranging from a low of $22 to a high of $30, with a standard deviation of $4.04. While the lowest estimate indicates an increase of 51.5% from the curre ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock ali ...

If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh 30 kg (66 lbs.) or greater SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and th ...

ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Ind ...

vgajic/E+ via Getty Images Investment Overview The San Diego based biotech ARS Pharmaceutical's (NASDAQ:SPRY) share price is up nearly 120% year-to-date, and at the end of August, shares made a quick >20% gain, after its lead and only product, neffy, a nasal spray, was approved for commercial use by the FDA, ahead of schedule, for the treatment of Type I Allergic Reactions. In its latest, Q2 2024 quarterly report / 10Q submission, ARS provides basic information around neffy as follows: ARS-1 (brand name nef ...

EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU European Commission decision follows FDA approval in the United States on August 9, 2024 SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to the development of products to better protect patients from severe allergic reactions that could lead to anaphylaxis, announc ...